Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Oral Oncol. Author manuscript; available in PMC 2017 May 1.
Published in final edited form as:
PMCID: PMC5089835

Oncolytic Adenoviruses Targeted to Human Papilloma Virus-Positive Head and Neck Squamous Cell Carcinomas

Christopher J. LaRocca, MD,a Joohee Han, BS,a Amanda R. Oliveira, DVM, MS,a Julia Davydova, MD, PhD,a,b Mark Herzberg, DDS, PhD,c Rajaram Gopalakrishnan, BDS, PhD,c and Masato Yamamoto, MD, PhDa,b,d



In recent years, the incidence of Human Papilloma Virus (HPV)-positive head and neck squamous cell carcinomas (HNSCC) has markedly increased. Our aim was to design a novel therapeutic agent through the use of conditionally replicative adenoviruses (CRAds) that are targeted to the HPV E6 and E7 oncoproteins.


Each adenovirus included small deletion(s) in the E1a region of the genome (Δ24 or CB016) intended to allow for selective replication in HPV-positive cells. In vitro assays were performed to analyze the transduction efficiency of the vectors and the cell viability following viral infection. Then, the UPCI SCC 090 cell line (HPV-positive) was used to establish subcutaneous tumors in the flanks of nude mice. The tumors were then treated with either one dose of the virus or four doses (injected every fourth day).


The transduction analysis with luciferase-expressing viruses demonstrated that the 5/3 fiber modification maximized virus infectivity. In vitro, both viruses (5/3Δ24 and 5/3CB016) demonstrated profound oncolytic effects. The 5/3CB016 virus was selective for only HPV-positive HNSCC cells, whereas the 5/3Δ24 virus killed HNSCC cells regardless of HPV status. In vivo, single injections of both viruses demonstrated anti-tumor effects until only 6–8 days following viral inoculation. However, after four viral injections, there was statistically significant reduction in tumor growth when compared to the control group (p<0.05).


CRAds targeted to HPV-positive HNSCCs demonstrated excellent in vitro and in vivo therapeutic effects, and they have the potential to be clinically translated as a novel treatment modality for this emerging disease.

Keywords: Human Papillomavirus, Head and Neck Cancer, Squamous Cell Carcinoma, Oncolytic Adenovirus


In the United States, approximately 55,000 new cases of head and neck cancers were diagnosed in 2014 [1]. These cancers encompass a heterogeneous group of malignances including oral, oropharyngeal, pharyngeal, and laryngeal tumors. Importantly, the vast majority of these malignancies are squamous cell carcinomas [2]. In recent years, the incidence of Human Papilloma Virus (HPV)-positive head and neck squamous cell carcinomas (HNSCC) has markedly increased [3]. Specifically, the population level incidence of HPV-positive oropharyngeal squamous cell carcinomas increased by 225% from 1998 to 2004, while there was a concomitant 50% decline in the incidence of their HPV-negative counterparts during the same time period [4]. Additionally, the annual number of HPV-positive oropharyngeal cancers is projected to surpass that of cervical cancers by 2020 [4].

HPV-positive HNSCCs are considered distinct biologic entities when compared to those without the viral association. When compared to HPV-negative HNSCCs, HPV-positive tumors tend to occur in younger individuals without exposures to the traditional risk factors such as smoking and alcohol use [5, 6]. While HPV-positive HNSCCs do have an improved survival when compared to HPV-negative tumors [7], it is key to note that there is still some difficulty with the management of distant recurrences. Distant metastases associated with HPV-positive tumors have been shown to occur in multiple organs, unusual sites, and after longer intervals when compared to those distant metastases in HPV-negative tumors [8]. These distant lesions are known to be a major cause of death in patients with oropharyngeal squamous cell carcinomas [9].

Much of the aforementioned differences in behavior can be attributed to the fact that HPV-positive tumors have distinct mechanisms of oncogenesis. Among the various HPV subtypes, HPV 16 and 18 (high risk) are most often associated with malignant transformation, and 95% of HPV-positive tumors within the oral cavity and oropharynx contained HPV 16 DNA [10, 11]. Unlike their low-risk counterparts, DNA from HPV 16 and 18 are known to contribute to the immortalization of human keratinocytes [12]. More specifically, it is the E6 and E7 oncoproteins encoded by only the high risk subtypes have been shown to transform and immortalize primary human keratinocytes [13, 14]. The E6 protein suppresses the function of p53 by promoting its degradation through the ubiquitin-dependent protease system [15, 16] and downregulates p53 by binding to the co-activator p300/CBP [17]. E7 binds to the retinoblastoma (Rb) protein to disrupt interactions with the E2F transcription factor, which results in the release of free E2F in its active form to potentiate tumorigenesis [18, 19].

The increasing incidence of HPV-positive HNSCCs and their unique biology have necessitated the development of novel treatment methods. Adenovirus-based vectors have emerged as a powerful tool for the treatment of many types of cancers, and could have a great deal of applicability for the treatment of HPV-positive HNSCCs. Specifically, conditionally replicative adenoviruses (CRAd) are attractive as therapeutic agents as they have the potential to selectively replicate within the target cells of interest. Importantly, adenoviruses and the HPV E6/E7 oncoproteins interact with similar regulatory proteins to modulate the cell cycle. The adenovirus E1A protein is the first unit transcribed and its products are key components for successful adenoviral replication. The CR1 region of the adenovirus E1A protein has been shown to bind to p300, which then interacts with and suppresses the function of p53 [20]. Additionally, the CR2 region of the E1A protein is able to disrupt the interaction between the pRb-E2F complex, rendering the retinoblastoma protein unable to perform its normal cell cycle checkpoint functions [19, 21].

Adenoviral replication can be controlled by the inclusion of a tumor-specific promoter (e.g. Cox2, CXCR4) within the adenoviral genome. Alternatively, vectors can be designed with genomic deletions to confer replication selectivity. Due to the similarities in the way the HPV and adenovirus interact with cell cycle regulators, deletion in the adenovirus E1 region can be used to target HPV positive tumors. For example, a 24 base pair deletion (Δ24) in the E1A CR2 region (the area normally responsible for biding to the retinoblastoma protein) has been used to selectively target HPV-positive tumors [22]. Furthermore, another CRAd (CB016) that contains an additional deletion in the adenovirus E1A CR1 region (along with the Δ24 deletion) has been developed [23]. The deletions in the adenoviral genome within the Δ24 and CB016 viruses do not allow for the encoding of key viral protein products that would normally allow for viral replication. However, within HPV positive cells that express the E6 and E7 oncoproteins, adenoviral replication proceeds due to functional transcomplementation from the HPV proteins [24, 25].

In this study, we employed the Δ24 and CB016 conditionally replicating adenoviruses in the treatment of HPV-positive HNSCCs. The vectors ability to selectively replicate within and kill HPV-positive HNSCCs was demonstrated in vitro. Thereafter, the oncolytic potential of the adenoviruses was studied in a xenograft model using nude mice. The results of these experiments provide insight into the clinical utility of adenovirus-based therapy for the treatment of HPV-positive HNSCCs.

Materials and Methods

Cell Lines and Culture Conditions

Two human HPV-negative (SCC-4, SCC-15 [provided by Dr. David Wong, University of California Los Angeles]) and three HPV-positive HNSCC cell lines (93VU147T [provided by Dr. Hans Joenje, VU University Medical Center, The Netherlands], UPCI SCC 090 [gift from Dr. Suzanne Gollin, University of Pittsburgh], and UM047 [obtained from Dr. Thomas Carey, University of Michigan]) were cultured in Dulbecco’s modified Eagle medium (DMEM) (Mediatech, Herndon, VA). All cell lines were supplemented with 10% (V/V) fetal bovine serum and a 1% penicillin-streptomycin mixture (100 IU/mL and 100 μg/mL, respectively). They were maintained as adherent monolayers at 37°C in a humidified incubator with 5% CO2 in air.

Adenoviral Vectors

The 5/3 Δ24 ΔE3-ADP-Luc and 5/3 CB016 ΔE3-ADP-Luc vectors (hereafter referred to as 5/3 Δ24 and 5/3 CB016 respectively) were based on adenovirus type 5 (Ad5) (Figure 1). The adenoviral vector plasmids encoding Δ24 and CB016 mutations (pAdΔ24 and pCB016 respectively) [22, 23] (provided by Drs. Ramon Alemany and Cristina Balgué) were recombined with the pAd-ΔE3-ADP-Luc adenoviral backbone as previously described [26]. Briefly, in the pAd-ΔE3-ADP-Luc structure, most of the non-essential adenovirus E3 genes were deleted (with the exception of the adenovirus death protein (ADP) which is designed to facilitate viral spread and oncolysis) and replaced with the luciferase reporter gene [26, 27].

Figure 1
Schematic of oncolytic adenoviruses targeted to HPV-positive HNSCCs

For infectivity enhancement analysis, CMV promoter-driven luciferase expression vectors with RGD-modified Ad5 fiber (RGD-CMV-Luc), Ad5/Ad3-chimeric fiber (5/3-CMV-Luc), or wild type Ad5 fiber (Ad5-CMV-Luc) were used. All of these replication-incompetent Ad vectors are identical, except for their genetically modified fibers. The Ad 5/3 chimeric fiber replaces the knob region of Ad5 with that of Ad3, while the RGD fiber adds an arginine-glycine-aspartate-containing peptide into the HI loop of the fiber knob domain [28]. The wild type Ad5 (Ad5Wt) and the 5/3 ΔE3-ADP-Luc viruses were utilized as non-selective replicative control vectors [26].

All viruses were propagated in the 293 cell line, purified by double cesium chloride density gradient ultracentrifugation, and dialyzed against phosphate-buffered saline (PBS) with 10% glycerol. The vectors were titrated using a plaque-forming assay, and the viral particle (vp) number was measured spectrophotometrically.

Analysis of Fiber Structure for Optimized Infectivity

The human HNSCC cell lines (SCC-4, SCC-15, 93VU147T, UPCI SCC 090, and UM047) were cultured as above in 24-well plates (5×104 cells/well). On the following day, they were infected with replication-deficient (CMV promoter-driven), luciferase expressing vectors with the Ad 5 Wt, RGD, or chimeric Ad 5/3 fiber at a titer of 100 viral particles (vp)/cell. Two days after infection, the cells were lysed with 100 μl of cell culture lysis buffer, and the luciferase activity was determined with the Luciferase Assay System (Promega, Madison, WI). Results were standardized with cellular protein concentration as quantitated using the DC protein assay (Bio-Rad, Hercules, CA).

Analysis of Selective Viral Replication

The 5/3 Δ24 and 5/3 CB016 vectors were used to infect the same five human HNSCC cell lines (24-well plates; 5×104 cells/well) at a titer of 100 vp/cell. A replication deficient vector (5/3-CMV-Luc) and wild type replication vector (5/3 ΔE3-ADP-Luc) were used as non-selective controls. Two days after infection, the cells were lysed with 100 μl of cell culture lysis buffer, and the luciferase activity was determined with the Luciferase Assay System (Promega, Madison, WI). Results were standardized with cellular protein concentration quantitated using the DC protein assay (Bio-Rad, Hercules, CA).

Qualitative Cytocidal Effect

Four human HNSCC cell lines (SCC-15, 93VU147T, UPCI SCC 090, and UM047) were cultured in 24-well plates, and a viral infection was performed the next day using a titer of 100 vp/cell. Vectors included a wild type control (Ad5 Wt), a non-replicating control (5/3 CMV Luc), and two CRAds (5/3 Δ24 and 5/3 CB016). After 3, 6, and 9 days of cultivation, the cells were fixed with 10% buffered formalin for 10 minutes, stained with 1% crystal violet in 70% ethanol for 20 minutes, washed 3 times with tap water and allowed to air dry.

Quantitative Analysis of Cell Viability

Three human HNSCC cell lines (SCC-15, 93VU147T, UPCI SCC 090) were cultured in 96-well plates (3,000 cells/well), and subsequently infected with adenoviral vectors 24 hours thereafter at strengths of 1, 10, or 100 vp/cell. The number of surviving cells was estimated using a colorimetric method (Cell Titer Aqueous One Solution Cell Proliferation Assay: Promega; Madison, WI) according to the manufacturer’s instructions. Absorbance attributable to living cells was measured at a wavelength of 490 nm in a FLUOstar Omega spectrophotometer (BMG Labtech, Ortenberg, Germany). The number of infected, living cells at each time point was normalized to the number of uninfected living cells.

In Vivo Tumor Growth Analyses

Using the UPCI SCC 090 HPV-positive HNSCC cell line, 2×106 cells (in 100 μL of PBS) were inoculated subcutaneously into the flanks of female athymic nude mice to generate tumors. When the tumor nodules achieved a diameter of approximately 6–8 mm, virus was injected intratumorally. For the single injection experiment, a dose 3.5×1010vp/tumor was used. For the multiple injection experiment, a viral dose of 3.5×1011vp/tumor was used, and a total of four intratumoral injections were delivered. The tumor diameter was measured twice per week with calipers. The tumor volume was calculated using the following formula: Tumor Volume = (Width2 × Length)/2. All procedures were carried out according to protocols approved by the Institutional Animal Care and Use Committee (IACUC) of the University of Minnesota.

Statistical Methods

Statistical analyses of in vitro and in vivo viral effects were performed using Excel (Microsoft, Redmond, WA). Differences in viral infectivity and replication, cell viability, and the relative tumor volumes of in vivo treatment groups were analyzed using the Student’s t-test. The results were considered statistically significant when a two-tailed P value was less than 0.05. Data are expressed as a mean ± standard deviation.


Augmented Viral Infectivity due to Fiber Modification

Replication-deficient vectors (Ad5-CMV-Luc, RGD-CMV-Luc, and 5/3-CMV-Luc) expressing the luciferase transgene and equipped with one of three different fibers (Ad 5 Wt, RGD, or Ad 5/3) were used to analyze viral infectivity in five HNSCC cell lines (Figure 2). In all cell lines tested (three HPV-positive and two HPV-negative), luciferase expression reflecting the extent of viral infectivity was significantly greater with the Ad 5/3 chimeric fiber than the Ad 5 Wt or RGD fibers (p<0.01). Since the Ad 5/3 chimeric fiber modification demonstrated the greatest infectivity enhancement in both HPV-positive and HPV-negative cell lines, it was used exclusively in all additional studies.

Figure 2
Infectivity maximized with the Ad 5/3 fiber

Replication Selectivity of E1-Mutant Viruses

The replication of the 5/3 CB016 and 5/3 Δ24 viruses was tested in the HPV-negative (SCC-4 and SCC-15) and HPV-positive cell lines (93VU147T, UM047, and UPCI SCC 090) (Figure 3). The 5/3 ΔE3-ADP-Luc virus was used as a positive control vector as it demonstrated ubiquitous replication that was independent of HPV status (all data was then expressed as a percentage relative to this control virus), and the 5/3-CMV-Luc virus served as a replication-deficient (negative) control. The 5/3 Δ24 virus demonstrated a high level of viral replication in all cell lines, which was similar to the replicating control vector. Notably, the 5/3 CB016 vector replicated selectively in the HPV-positive cell lines [UPCI (49%) and UM047 (36%)], and demonstrated only 5 to 10% replication in the HPV-negative cell lines (SCC-4 and SCC-15). These results indicated that the replication of 5/3 CB016 virus was quite selective, while 5/3 Δ24 virus showed stronger but HPV independent replication.

Figure 3
Selective replication in HPV-positive HNSCC cells

In Vitro Cytocidal Effects of HPV-targeted CRAds

To demonstrate the qualitative cytocidal effects of the 5/3 CB016 and 5/3 Δ24 viruses, a crystal violet stain was performed at multiple time points following viral infection (Figure 4). The 5/3-CMV-Luc (replication deficient) and Ad5 Wt vectors were used as controls. In the HPV-positive cell lines, the 5/3 CB016 virus killed cells effectively in two of the three cell lines at early time points and by day 9 there was total cell death in all HPV-positive cells. Additionally, the 5/3 CB016 virus had minimal effect on the HPV-negative cell line (SCC-15). In contrast, the 5/3 Δ24 virus killed all cell lines efficiently, regardless of HPV status.

Figure 4
In vitro qualitiative cell viability

To quantitate the cytocidal effect of the vectors, cells were infected with increasing doses of the 5/3 CB016 and 5/3 Δ24 viruses, and the percentages of living cells over time were analyzed (Figure 5). At day 3, the 5/3 Δ24 virus showed strong cytocidal effects at low viral titers. By day 7 after viral infection, there were no viable cells after infection with the lowest titer (1 vp/cell) in all cell lines. In contrast, at day 3, the CB016 virus at the highest titer (100 vp/cell) tested caused only modest cell death in the 93VU147T cell line (HPV-positive). At the later time point, the same titer of the 5/3 CB016 virus killed over 80% of the 93VU147T cell line. Moreover, the 5/3 CB016 virus had a minimal effect on the HPV-negative (SCC-15) cell line at both time points.

Figure 5
Quantitative cell viability

Limited Antitumor Effect of a Single Intratumoral Injection

The in vivo antitumor effects of the vectors were assessed with a nude mouse model using subcutaneous xenografts established with the UPCI SCC 090 (HPV-positive) cell line (Figure 6). The resulting tumors were then directly injected with a single dose of 3.5 × 1010 viral particles. Up until day 4, the 5/3 CB016 vector demonstrated an equivalent tumor growth suppression to the wild type vector (when compared to untreated controls) after which time the 5/3 CB016 group demonstrated tumor regrowth. Additionally, the antitumor effect of 5/3 Δ24 virus persisted until approximately day 12 (similar to wild type vector) when compared to the untreated controls, after which it too demonstrated regrowth when compared to the wild type vector. It was clear that both the 5/3 Δ24 and 5/3 CB016 vectors demonstrated tumor growth suppression after a single intratumoral injection, but the effect was short-lived.

Figure 6
Anti-tumor effect of a single adenovirus injection

Multiple Intratumoral Injections Yields Improved Antitumor Effect

As the single intratumoral injections failed to sustain antitumor effects, subcutaneous xenografts were established in the same fashion as the previous experiment, and four intratumoral injections (4 day intervals) were performed using a dose of 3.5 × 1011vp/tumor (Figure 7). The growth curves of the treatment groups and control group diverged soon after the initial injection of virus, and continued to separate throughout the experiment. The 5/3 Δ24 and 5/3 CB016 viruses significantly suppressed tumor growth (p<0.05) for up to 30 days when compared to the untreated controls. Additionally, the 5/3 Δ24 group demonstrated tumor regression with a relative volume of less than 1.0 from day 9 until day 26 (Figure 7 inset).

Figure 7
Improved In vivo therapeutic effect of multiple injections


As a way to develop therapeutics targeting HPV viral protein expression, our research group has employed conditionally replicating adenoviruses (CRAd) for the treatment of HPV-positive HNSCCs. Unlike some other virus-associated cancers, HPV-induced cancers continue to express key oncoproteins even after carcinogenesis [29]. Our viral vectors are designed to target and utilize this continued oncoprotein expression for therapeutic purposes. In these studies, we have demonstrated the improved infectivity afforded with a 5/3 fiber modification, as well as the selective replication of the 5/3 CB016 virus only within the HPV-positive cell lines. Furthermore, we also show the impressive in vivo oncolytic effect of multiple intratumoral injections in a subcutaneous xenograft model.

The coxsackie and adenovirus receptor (CAR) is the primary receptor for adenovirus type 5; however, it is expressed at low and often variable levels in HNSCCs [30, 31]. Furthermore, the levels of CAR expression have also been shown to decrease with the malignant progression of HNSCCs [32]. Low CAR levels on target tumor cells have been a limiting factor with certain gene therapy approaches for some time, but modification of the adenovirus capsid proteins has been shown to improve infectivity in both HNSCCs as well as other cancers [33, 34]. Previously, our group has used an Ad5/Ad3 fiber in the setting of adenoviral therapy for pancreatic cancer [27]. Based on this experience, we have applied the same fiber modification to overcome the CAR deficiency for HNSCCs. This particular fiber replaces the Ad5 knob with that of Ad3, the receptor of which has been recently identified to be human CD46 and desmoglein 2 [3537]. Our data indicate that the Ad 5/3 fiber significantly improves infectivity when compared to either a RGD or wild type fiber, and the Ad 5/3 fiber was therefore used in these studies.

The 5/3 CB016 and 5/3 Δ24 vectors were compared to a replication competent control virus to analyze their replication profile. The 5/3 CB016 virus selectively replicated in HPV-positive HNSCC cells, while the 5/3 Δ24 virus demonstrated a high degree of non-selective replication. The cytocidal effect of the viruses analyzed by both qualitative and quantitative assays exhibited a HPV-targeted cell-killing effect of the 5/3 CB016 virus and a strong (albeit non-selective) effect of the 5/3 Δ24 virus, which corresponded well to the aforementioned replication profile. It is likely that the 5/3 Δ24 virus’ single deletion in the adenoviral E1A CR2 region was not enough to confer selectivity in this setting, thereby suggesting that the additional deletion in the CR1 region is quite necessary to achieve selective replication. These results are not unexpected as an adenoviral infection in raft cultures of keratinocytes expressing HPV 18 E6 and E7, the CB016 virus replicated selectively, while the Δ24 virus did not [23].

In our in vivo studies, only a short-lived antitumor effect resulted from a single adenovirus injection. While this was encouraging, we wanted to further optimize the therapeutic utility of the vectors. This observation led us to design a multiple injection experiment where four intratumoral doses of virus were delivered within two weeks. The multiple injection regimen conferred a profound improvement in oncolytic effect, and this statistically significant difference was present from a very early time point and persisted throughout the duration of the experiment. In fact, clinical trials employing multiple intratumoral injections of replication-selective adenoviruses have been conducted for the treatment of head and neck cancers [38]. Therefore, a multiple injection regimen is a reasonable protocol for these types of tumors, considering that HNSCCs usually have relatively accessible anatomic location in patients.

There have also been clinical trials specifically using derivatives of the Δ24 virus for the treatment of solid tumors in patients. For example, the Δ24 virus has been used in the treatment of gynecologic malignancies, and it is notable that there was no significant toxicities directly attributed to the administration of the virus during these trials [39, 40]. While we do not address the bio-toxicities or safety profile of the vectors in this study, it is crucial to note that similar vectors have already been tested in humans with minimal adverse effects. We would anticipate that our 5/3 CB016 vector, given its selective replication, would also show a favorable toxicity profile.

HPV-associated tumors are becoming more widespread, and this is especially true for head and neck cancers. Distant metastases continue to present treatment challenges for clinicians, and these difficulties translate into increased morbidity and mortality for patients. Our oncolytic adenoviruses (5/3 Δ24 and 5/3 CB016) represent a novel application of viral therapy to address a burgeoning problem in clinical medicine. This work is an important step towards clinical translation and maximizing the vectors’ potential for the treatment of HPV-positive HNSCCs.


We are grateful to Drs. Ramon Alemany and Cristina Balagué for providing the plasmids encoding the CB016 and Δ24 mutations


The project was funded by a University of Minnesota Academic Health Center Faculty Research Development Grant (MY, MH, RG)


Human Papilloma Virus
Head and neck squamous cell carcinoma
Conditionally replicating adenovirus
Adenovirus death protein


Conflicts of Interests

The authors have none to disclose.


1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29. [PubMed]
2. Mehanna H, Paleri V, West CM, Nutting C. Head and neck cancer–Part 1: Epidemiology, presentation, and prevention. BMJ. 2010;341:c4684. [PubMed]
3. Pytynia KB, Dahlstrom KR, Sturgis EM. Epidemiology of HPV-associated oropharyngeal cancer. Oral Oncol. 2014;50:380–6. [PMC free article] [PubMed]
4. Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011;29:4294–301. [PMC free article] [PubMed]
5. Fakhry C, Psyrri A, Chaturvedhi A. HPV and head and neck cancers: state-of-the-science. Oral Oncol. 2014;50:353–5. [PubMed]
6. Gillison ML. Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity. Semin Oncol. 2004;31:744–54. [PubMed]
7. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363:24–35. [PMC free article] [PubMed]
8. Huang SH, Perez-Ordonez B, Liu FF, Waldron J, Ringash J, Irish J, et al. Atypical clinical behavior of p16-confirmed HPV-related oropharyngeal squamous cell carcinoma treated with radical radiotherapy. Int J Radiat Oncol Biol Phys. 2012;82:276–83. [PubMed]
9. Spector ME, Gallagher KK, Light E, Ibrahim M, Chanowski EJ, Moyer JS, et al. Matted nodes: poor prognostic marker in oropharyngeal squamous cell carcinoma independent of HPV and EGFR status. Head Neck. 2012;34:1727–33. [PMC free article] [PubMed]
10. Herrero R, Castellsague X, Pawlita M, Lissowska J, Kee F, Balaram P, et al. Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst. 2003;95:1772–83. [PubMed]
11. Huang LW, Chao SL, Lee BH. Integration of human papillomavirus type-16 and type-18 is a very early event in cervical carcinogenesis. J Clin Pathol. 2008;61:627–31. [PubMed]
12. Schlegel R, Phelps WC, Zhang YL, Barbosa M. Quantitative keratinocyte assay detects two biological activities of human papillomavirus DNA and identifies viral types associated with cervical carcinoma. EMBO J. 1988;7:3181–7. [PubMed]
13. Munger K, Phelps WC, Bubb V, Howley PM, Schlegel R. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J Virol. 1989;63:4417–21. [PMC free article] [PubMed]
14. Hawley-Nelson P, Vousden KH, Hubbert NL, Lowy DR, Schiller JT. HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO J. 1989;8:3905–10. [PubMed]
15. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 1990;63:1129–36. [PubMed]
16. Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science. 1990;248:76–9. [PubMed]
17. Zimmermann H, Degenkolbe R, Bernard HU, O’Connor MJ. The human papillomavirus type 16 E6 oncoprotein can down-regulate p53 activity by targeting the transcriptional coactivator CBP/p300. J Virol. 1999;73:6209–19. [PMC free article] [PubMed]
18. Dyson N, Howley PM, Munger K, Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science. 1989;243:934–7. [PubMed]
19. Chellappan S, Kraus VB, Kroger B, Munger K, Howley PM, Phelps WC, et al. Adenovirus E1A, simian virus 40 tumor antigen, and human papillomavirus E7 protein share the capacity to disrupt the interaction between transcription factor E2F and the retinoblastoma gene product. Proc Natl Acad Sci U S A. 1992;89:4549–53. [PubMed]
20. Sang N, Avantaggiati ML, Giordano A. Roles of p300, pocket proteins, and hTBP in E1A-mediated transcriptional regulation and inhibition of p53 transactivation activity. J Cell Biochem. 1997;66:277–85. [PubMed]
21. Whyte P, Williamson NM, Harlow E. Cellular targets for transformation by the adenovirus E1A proteins. Cell. 1989;56:67–75. [PubMed]
22. Fueyo J, Gomez-Manzano C, Alemany R, Lee PS, McDonnell TJ, Mitlianga P, et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene. 2000;19:2–12. [PubMed]
23. Balague C, Noya F, Alemany R, Chow LT, Curiel DT. Human papillomavirus E6E7-mediated adenovirus cell killing: selectivity of mutant adenovirus replication in organotypic cultures of human keratinocytes. J Virol. 2001;75:7602–11. [PMC free article] [PubMed]
24. Steinwaerder DS, Carlson CA, Lieber A. Human papilloma virus E6 and E7 proteins support DNA replication of adenoviruses deleted for the E1A and E1B genes. Mol Ther. 2001;4:211–6. [PubMed]
25. Wong HK, Ziff EB. The human papillomavirus type 16 E7 protein complements adenovirus type 5 E1A amino-terminus-dependent transactivation of adenovirus type 5 early genes and increases ATF and Oct-1 DNA binding activity. J Virol. 1996;70:332–40. [PMC free article] [PubMed]
26. Davydova J, Gavrikova T, Brown EJ, Luo X, Curiel DT, Vickers SM, et al. In vivo bioimaging tracks conditionally replicative adenoviral replication and provides an early indication of viral antitumor efficacy. Cancer Sci. 2010;101:474–81. [PMC free article] [PubMed]
27. Armstrong L, Davydova J, Brown E, Han J, Yamamoto M, Vickers SM. Delivery of interferon alpha using a novel Cox2-controlled adenovirus for pancreatic cancer therapy. Surgery. 2012;152:114–22. [PMC free article] [PubMed]
28. Davydova J, Le LP, Gavrikova T, Wang M, Krasnykh V, Yamamoto M. Infectivity-enhanced cyclooxygenase-2-based conditionally replicative adenoviruses for esophageal adenocarcinoma treatment. Cancer Res. 2004;64:4319–27. [PubMed]
29. Parfenov M, Pedamallu CS, Gehlenborg N, Freeman SS, Danilova L, Bristow CA, et al. Characterization of HPV and host genome interactions in primary head and neck cancers. Proc Natl Acad Sci U S A. 2014;111:15544–9. [PubMed]
30. Kasono K, Blackwell JL, Douglas JT, Dmitriev I, Strong TV, Reynolds P, et al. Selective gene delivery to head and neck cancer cells via an integrin targeted adenoviral vector. Clin Cancer Res. 1999;5:2571–9. [PubMed]
31. Suominen E, Toivonen R, Grenman R, Savontaus M. Head and neck cancer cells are efficiently infected by Ad5/35 hybrid virus. J Gene Med. 2006;8:1223–31. [PubMed]
32. Wunder T, Schumacher U, Friedrich RE. Coxsackie adenovirus receptor expression in carcinomas of the head and neck. Anticancer Res. 2012;32:1057–62. [PubMed]
33. Dehari H, Ito Y, Nakamura T, Kobune M, Sasaki K, Yonekura N, et al. Enhanced antitumor effect of RGD fiber-modified adenovirus for gene therapy of oral cancer. Cancer Gene Ther. 2003;10:75–85. [PubMed]
34. Yamamoto M, Curiel DT. Current issues and future directions of oncolytic adenoviruses. Mol Ther. 2010;18:243–50. [PubMed]
35. Wang H, Li ZY, Liu Y, Persson J, Beyer I, Moller T, et al. Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14. Nat Med. 2011;17:96–104. [PMC free article] [PubMed]
36. Fleischli C, Sirena D, Lesage G, Havenga MJ, Cattaneo R, Greber UF, et al. Species B adenovirus serotypes 3, 7, 11 and 35 share similar binding sites on the membrane cofactor protein CD46 receptor. J Gen Virol. 2007;88:2925–34. [PubMed]
37. Sirena D, Lilienfeld B, Eisenhut M, Kalin S, Boucke K, Beerli RR, et al. The human membrane cofactor CD46 is a receptor for species B adenovirus serotype 3. J Virol. 2004;78:4454–62. [PMC free article] [PubMed]
38. Nemunaitis J, Khuri F, Ganly I, Arseneau J, Posner M, Vokes E, et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol. 2001;19:289–98. [PubMed]
39. Kim KH, Dmitriev IP, Saddekni S, Kashentseva EA, Harris RD, Aurigemma R, et al. A phase I clinical trial of Ad5/3-Delta24, a novel serotype-chimeric, infectivity-enhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer. Gynecol Oncol. 2013;130:518–24. [PMC free article] [PubMed]
40. Kimball KJ, Preuss MA, Barnes MN, Wang M, Siegal GP, Wan W, et al. A phase I study of a tropism-modified conditionally replicative adenovirus for recurrent malignant gynecologic diseases. Clin Cancer Res. 2010;16:5277–87. [PMC free article] [PubMed]